Arun Sharma

Arun Sharma

Auto-generated profile, based on publicly available information

Arun Sharma

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2016 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PBPaul W Burridge
Paul W Burridge
YLYong Fuga Li
Yong Fuga Li
EMElena Matsa
Elena Matsa
HWHaodi Wu
Haodi Wu
SOSang-Ging Ong
Sang-Ging Ong
JWJoseph C Wu
Joseph C Wu

15 February 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ASArun Sharma
Arun Sharma
PBPaul W. Burridge
Paul W. Burridge
WMWesley L. McKeithan
Wesley L. McKeithan
RSRicardo Serrano
Ricardo Serrano
PSPraveen Shukla
Praveen Shukla
JWJoseph C. Wu
Joseph C. Wu
High-throughput screening of drugs with human induced pluripotent stem cell–derived cardiomyocytes reveals a “cardiac safety index.”

10 March 2020 in Circulation
Verified
Journal Article
Open access
PDF file
CTChristopher N. Toepfer
Christopher N. Toepfer
AGAmanda C. Garfinkel
Amanda C. Garfinkel
GVGabriela Venturini
Gabriela Venturini
HWHiroko Wakimoto
Hiroko Wakimoto
GRGiuliana Repetti
Giuliana Repetti
CSChristine Seidman
Christine Seidman
Background: Hypertrophic cardiomyopathy (HCM) is caused by pathogenic variants in sarcomere protein genes that evoke hypercontractility, poor relaxation, and increased energy consumption by the heart and increased patient risks for arrhythmias and heart failure. Recent studies show that pathogenic missense variants in myosin, the molecular motor of the sarcomere, are clustered in residues that participate in dynamic conformational states of sarcomere proteins. We hypothesized that these conformations are essential to adapt contractile output for energy conservation and that pathophysiology of HCM results from destabilization of these conformations. Methods: We assayed myosin ATP binding to define the proportion of myosins in the super relaxed state (SRX) conformation or the disordered relaxed state (DRX) conformation in healthy rodent and human hearts, at baseline and in response to reduced hemodynamic demands of hibernation or pathogenic HCM variants. To determine the relationships between myosin conformations, sarcomere function, and cell biology, we assessed contractility, relaxation, and cardiomyocyte morphology and metabolism, with and without an allosteric modulator of myosin ATPase activity. We then tested whether the positions of myosin variants of unknown clinical significance that were identified in patients with HCM, predicted functional consequences and associations with heart failure and arrhythmias. Results: Myosins undergo physiological shifts between the SRX conformation that maximizes energy conservation and the DRX conformation that enables cross-bridge formation with greater ATP consumption. Systemic hemodynamic requirements, pharmacological modulators of myosin, and pathogenic myosin missense mutations influenced the proportions of these conformations. Hibernation increased the proportion of myosins in the SRX conformation, whereas pathogenic variants destabilized these and increased the proportion of myosins in the DRX conformation, which enhanced cardiomyocyte contractility, but impaired relaxation and evoked hypertrophic remodeling with increased energetic stress. Using structural locations to stratify variants of unknown clinical significance, we showed that the variants that destabilized myosin conformations were associated with higher rates of heart failure and arrhythmias in patients with HCM. Conclusions: Myosin conformations establish work-energy equipoise that is essential for life-long cellular homeostasis and heart function. Destabilization of myosin energy-conserving states promotes contractile abnormalities, morphological and metabolic remodeling, and adverse clinical outcomes in patients with HCM. Therapeutic restabilization corrects cellular contractile and metabolic phenotypes and may limit these adverse clinical outcomes in patients with HCM.

10 September 2013 in Circulation
Verified
Journal Article
Closed access
PDF file
ENEnrique G. Navarrete
Enrique G. Navarrete
PLPing Liang
Ping Liang
FLFeng Lan
Feng Lan
VSVerónica Sanchez-Freire
Verónica Sanchez-Freire
CSChelsey Simmons
Chelsey Simmons
JWJoseph C. Wu
Joseph C. Wu
Background—: Drug-induced arrhythmia is one of the most common causes of drug development failure and withdrawal from market. This study tested whether human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) combined with a low-impedance microelectrode array (MEA) system could improve on industry-standard preclinical cardiotoxicity screening methods, identify the effects of well-characterized drugs, and elucidate underlying risk factors for drug-induced arrhythmia. hiPSC-CMs may be advantageous over immortalized cell lines because they possess similar functional characteristics as primary human cardiomyocytes and can be generated in unlimited quantities. Methods and Results—: Pharmacological responses of beating embryoid bodies exposed to a comprehensive panel of drugs at 65 to 95 days postinduction were determined. Responses of hiPSC-CMs to drugs were qualitatively and quantitatively consistent with the reported drug effects in literature. Torsadogenic hERG blockers, such as sotalol and quinidine, produced statistically and physiologically significant effects, consistent with patch-clamp studies, on human embryonic stem cell–derived cardiomyocytes hESC-CMs. False-negative and false-positive hERG blockers were identified accurately. Consistent with published studies using animal models, early afterdepolarizations and ectopic beats were observed in 33% and 40% of embryoid bodies treated with sotalol and quinidine, respectively, compared with negligible early afterdepolarizations and ectopic beats in untreated controls. Conclusions—: We found that drug-induced arrhythmias can be recapitulated in hiPSC-CMs and documented with low impedance MEA. Our data indicate that the MEA/hiPSC-CM assay is a sensitive, robust, and efficient platform for testing drug effectiveness and for arrhythmia screening. This system may hold great potential for reducing drug development costs and may provide significant advantages over current industry standard assays that use immortalized cell lines or animal models.

1 March 2020 in Cell Stem Cell
Verified
Journal Article
Closed access
ASArun Sharma
Arun Sharma
SSSamuel Sances
Samuel Sances
MWMichael J. Workman
Michael J. Workman
CSClive N Svendsen
Clive N Svendsen

1 November 2016 in JACC
Verified
Journal Article
Closed access
PLPing Liang
Ping Liang
KSKarim Sallam
Karim Sallam
HWHaodi Wu
Haodi Wu
YLYingxin Li
Yingxin Li
IIIlanit Itzhaki
Ilanit Itzhaki
JWJoseph C. Wu
Joseph C. Wu